Avenue Therapeutics (Nasdaq:ATXI) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ATXI 주식 개요

전문 제약 회사인 애비뉴 테라퓨틱스는 신경 질환 치료를 위한 치료제 개발 및 상용화에 주력하는 기업입니다.

ATXI 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

지난 5년 동안 수입이 매년 29% 증가했습니다.

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

수익이 1백만 달러 미만인 경우 ( $0 )

의미 있는 시가총액이 없습니다. ( $3M )

최근 3개월간 주가 변동폭 심해

+ 1 더 많은 위험

Avenue Therapeutics, Inc. 경쟁사

Oxford Cannabinoid Technologies Holdings

OTCPK:OCTH.F

US$3.0m

SenesTech

NasdaqCM:SNES

US$3.2m

SciSparc

NasdaqCM:SPRC

US$2.7m

Petros Pharmaceuticals

NasdaqCM:PTPI

US$3.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Avenue Therapeutics
과거 주가
현재 주가	US$3.58
52주 최고치	US$93.75
52주 최저치	US$3.25
베타	-0.11
11개월 변경	-3.50%
3개월 변경 사항	-67.64%
1년 변경 사항	-95.79%
33년 변화	-99.88%
5년 변화	-99.95%
IPO 이후 변화	-99.96%

최근 뉴스 및 업데이트

Recent updates

Avenue Therapeutics shares slide on pricing $12M securities offering

Oct 07

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Sep 22

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

Jun 14

주주 수익률

	ATXI	US Pharmaceuticals	US 마켓
7D	4.7%	1.0%	0.3%
1Y	-95.8%	19.1%	22.5%

수익률 대 산업: ATXI 지난 1년 동안 17.4 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ATXI 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ATXI's price volatile compared to industry and market?
ATXI volatility
ATXI Average Weekly Movement	17.8%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.8%

안정적인 주가: ATXI 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ATXI 의 주간 변동성( 18% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2015	3	Alix MacLean	www.avenuetx.com

전문 제약 회사인 애비뉴 테라퓨틱스는 신경 질환 치료를 위한 치료제 개발 및 상용화에 주력하고 있습니다. 주요 제품 후보로는 척추 및 구근 근위축증 치료를 위한 임상 1b/2a상 시험 중인 AJ201, 수술 후 급성 통증 치료를 위한 정맥 내 트라마돌, 간질 및 공황 장애 치료를 위한 BAER-101 등이 있습니다. 이 회사는 2015년에 설립되었으며 플로리다 베이 하버 아일랜드에 본사를 두고 있습니다.

Avenue Therapeutics, Inc. 기본 사항 요약

Avenue Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ATXI 기본 통계
시가총액	US$3.45m
수익(TTM)	-US$7.18m
수익(TTM)	n/a

0.0x

P/S 비율

-0.5x

P/E 비율

ATXI 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ATXI 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$7.18m
수익	-US$7.18m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-7.63
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

ATXI 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ATXI 주식 개요

보상

위험 분석

Avenue Therapeutics, Inc. 경쟁사

OTCPK:OCTH.F

US$3.0m

NasdaqCM:SNES

US$3.2m

NasdaqCM:SPRC

US$2.7m

NasdaqCM:PTPI

US$3.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

Price target increased by 1,500% to US$900

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Now 570% overvalued after recent price rise

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Recent updates

Price target increased by 1,500% to US$900

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Now 570% overvalued after recent price rise

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

New major risk - Revenue and earnings growth

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

New major risk - Financial position

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

New major risk - Share price stability

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Executive Director recently bought US$251k worth of stock

Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. (NasdaqCM:ATXI) acquired Baergic Bio, Inc.

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $27.6 million.

Avenue Therapeutics shares slide on pricing $12M securities offering

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Avenue Therapeutics, Inc. Submits Type A Meeting Request and Related Briefing Documents to the FDA

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Avenue Therapeutics, Inc. Announces Management Changes

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

Avenue Therapeutics, Inc. Announces CEO Changes

Less than half of directors are independent

Avenue Therapeutics, Inc. Receives an Acknowledgement Letter from the Office of New Drugs of the Food and Drug Administration Regarding Avenue’s August 31, 2021 Formal Dispute Resolution Request

Avenue Therapeutics, Inc.(NasdaqCM:ATXI) dropped from Russell 3000E Index

Forecast breakeven pushed back to 2024

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Resubmits New Drug Application to the U.S. Food and Drug Administration for IV Tramadol

New 90-day high: US$6.93

How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Provides Regulatory Update for IV Tramadol

Avenue Therapeutics issues regulatory update for IV tramadol

Avenue Therapeutics, Inc. Announces Thomas G. Moore to Resign from the Board of Directors of the Company, Effective December 31, 2020

New 90-day low: US$2.95

Avenue Therapeutics, Inc. Receives Complete Response Letter from the FDA for IV Tramadol

New 90-day low: US$4.53

Price target lowered to US$9.00

New 90-day high - US$12.06

New 90-day high - US$11.68

주주 수익률

가격 변동성

회사 소개

Avenue Therapeutics, Inc. 기본 사항 요약

0.0x

-0.5x

수익 및 수익